Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Butaprost is a chemical compound that functions as a selective agonist for the prostaglandin E receptor (EP2). It exhibits an EC50 of 33 nM and a Ki of 2.4 μM when interacting with the murine EP2 receptor. However, Butaprost demonstrates lower activity against murine EP1, EP3, and EP4 receptors. Furthermore, it effectively attenuates fibrosis by inhibiting the TGF-β/Smad2 signaling pathway [1] [2] [3].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
500 μg | 35 days | $ 215.00 | |
1 mg | 35 days | $ 423.00 | |
5 mg | 35 days | $ 1,570.00 | |
10 mg | 35 days | $ 2,720.00 |
Description | Butaprost is a chemical compound that functions as a selective agonist for the prostaglandin E receptor (EP2). It exhibits an EC50 of 33 nM and a Ki of 2.4 μM when interacting with the murine EP2 receptor. However, Butaprost demonstrates lower activity against murine EP1, EP3, and EP4 receptors. Furthermore, it effectively attenuates fibrosis by inhibiting the TGF-β/Smad2 signaling pathway [1] [2] [3]. |
In vitro | Butaprost, at concentrations ranging from 1-100 nM over a period of 0.5-24 hours, significantly enhances Nur77 mRNA expression by approximately five-fold in hEP2-HEK293/EBNA cells, showing both dose- and time-dependency. The augmentation of Nur77 gene expression is mediated via the PKC pathway. Additionally, at a concentration of 50 μM for 24 hours, Butaprost mitigates TGF-β-stimulated fibronectin expression, Smad2 phosphorylation, and the epithelial-mesenchymal transition in Madin-Darby Canine Kidney (MDCK) cells. Western Blot analysis of HEK 293/EBNA cells, which stably express the human EP2 receptor, corroborates the five-fold increase in Nur77 mRNA expression after exposure to Butaprost. |
In vivo | Butaprost treatment (1-4 mg/kg; intraperitoneal injection; twice daily; for 7 days) effectively attenuates fibrosis development in male C57BL/6 mice (8 weeks of age; 21 g) subjected to unilateral ureteral obstruction surgery. This outcome is evidenced by the decreased gene and protein expression levels of α-smooth muscle actin, fibronectin, and collagen 1A1, indicating a significant mitigation of fibrosis. |
Synonyms | Butaprostum, TR-4979, (R)-Butaprost |
Molecular Weight | 408.57 |
Formula | C24H40O5 |
CAS No. | 69685-22-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Butaprost 69685-22-9 Butaprostum TR-4979 (R)-Butaprost TR 4979 TR4979 inhibitor inhibit